RAPT Therapeutics Announces Proposed Public Offering of Common Stock
November 17 2022 - 4:24PM
RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT” or the
“Company”), a clinical-stage, immunology-based biopharmaceutical
company focused on discovering, developing and commercializing oral
small molecule therapies for patients with significant unmet needs
in inflammatory diseases and oncology, today announced that it has
commenced an underwritten public offering of $75 million of its
common stock. In addition, RAPT expects to grant the underwriters a
30-day option to purchase up to an additional $11.25 million of its
common stock on the same terms and conditions. All of the shares of
common stock are being offered by RAPT. The proposed offering is
subject to market conditions, and there can be no assurance as to
whether or when the proposed offering may be completed or as to the
actual size or terms of the proposed offering.
J.P. Morgan, Evercore ISI, Guggenheim Securities and Cantor are
acting as joint book-running managers for the proposed
offering.
The offering is being made pursuant to a shelf registration
statement, including a base prospectus, filed by RAPT with
the Securities and Exchange Commission (the “SEC”), which
was declared effective by the SEC on November 16, 2020. The
offering may be made only by means of a prospectus supplement and
accompanying prospectus. A preliminary prospectus supplement and
accompanying prospectus relating to the offering will be filed with
the SEC and will be available on
the SEC’s website located at www.sec.gov. When
available, electronic copies of the preliminary prospectus
supplement and the accompanying prospectus may also be obtained
from: J.P. Morgan Securities LLC, c/o Broadridge Financial
Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by email at
prospectus-eq_fi@jpmchase.com or by telephone at (866) 803-9204;
Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East
52nd Street, 36th Floor, New York, NY 10055, by telephone at (888)
474-0200, or by email at ecm.prospectus@evercore.com; Guggenheim
Securities, LLC, Attention: Equity Syndicate Department, 330
Madison Avenue, 8th Floor, New York, NY 10017, by telephone at
(212) 518-9544 or by email at
GSEquityProspectusDelivery@guggenheimpartners.com; or Cantor
Fitzgerald & Co., Attention: Capital Markets, 499 Park Avenue,
6th Floor, New York, New York 10022, or by email at
prospectus@cantor.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
the registration or qualification under the securities laws of any
such state or jurisdiction.
About RAPT Therapeutics, Inc.
RAPT Therapeutics is a clinical stage
immunology-based biopharmaceutical company focused on discovering,
developing and commercializing oral small molecule therapies for
patients with significant unmet needs in inflammatory diseases and
oncology. Utilizing its proprietary discovery and development
engine, the Company is developing highly selective small molecules
designed to modulate the critical immune drivers underlying these
diseases. RAPT has discovered and advanced two unique drug
candidates, RPT193 and FLX475, each targeting C-C motif chemokine
receptor 4 (CCR4), for the treatment of inflammation and cancer,
respectively. The Company is also pursuing a range of targets that
are in the discovery stage of development.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including statements relating to RAPT’s expectations
regarding the completion, timing and size of the proposed public
offering. These statements are subject to significant risks and
uncertainties and actual results could differ materially from those
projected. RAPT cautions investors not to place undue reliance on
the forward-looking statements contained in this release. These
risks and uncertainties include, without limitation, risks and
uncertainties related to market conditions, the risk that the
proposed public offering will not be consummated on the terms or in
the amounts contemplated or otherwise, and the satisfaction of
customary closing conditions related to the proposed public
offering. Risks and uncertainties relating to RAPT and its business
can be found in the “Risk Factors” section of RAPT’s Form 10-Q for
the quarter ended September 30, 2022, filed with the SEC on
November 10, 2022, and in the preliminary prospectus supplement
related to the proposed public offering to be filed with the SEC.
RAPT undertakes no duty or obligation to update any forward-looking
statements contained in this release as a result of new
information, future events or changes in RAPT’s expectations,
except as required by law.
RAPT Media Contact:Aljanae
Reynoldsareynolds@wheelhouselsa.com
RAPT Investor Contact:Sylvia
Wheelerswheeler@wheelhouselsa.com
RAPT Therapeutics (NASDAQ:RAPT)
Historical Stock Chart
From Mar 2024 to Apr 2024
RAPT Therapeutics (NASDAQ:RAPT)
Historical Stock Chart
From Apr 2023 to Apr 2024